AZN vs MLYS
AZN: AstraZeneca is a major global biopharmaceutical company dedicated to delivering life-changing medicines across oncology, rare diseases, and diverse chronic conditions. MLYS: A clinical-stage biopharmaceutical company developing lorundrostat, a novel aldosterone synthase inhibitor targeting hypertension and cardiorenal diseases.
Side-by-side fundamentals
| Metric | AZN | MLYS | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $165.98 | $25.65 | |
| Market cap as of 2026-08-24 | $181.5B | $2.3B | |
| P/E as of 2026-08-24 | 23.44 | n/a | |
| PEG as of 2026-08-24 | 2.64 | -0.32 | MLYS lower |
| Net margin as of 2026-08-24 | +17.0% | n/a | |
| Gross margin as of 2026-08-24 | +81.3% | n/a | |
| Operating margin as of 2026-08-24 | +22.8% | n/a | |
| ROE as of 2026-08-24 | +21.7% | -27.9% | AZN higher |
| ROA as of 2026-08-24 | +9.1% | -27.0% | AZN higher |
| Debt / equity as of 2026-08-24 | 0.64 | 0.00 | MLYS lower |
| Revenue growth (YoY) as of 2026-08-24 | +8.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +9.8% | n/a | |
| Dividend yield as of 2026-08-24 | +2.3% | n/a | |
| Beta as of 2026-08-24 | 1.39 | 0.61 | |
| 1-year return as of 2026-08-21 close | +3.1% | +75.6% | MLYS higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.